sugemalimab + donafenib

**Sugemalimab + donafenib** is an investigational combination therapy consisting of two distinct pharmaceuticals: - **Sugemalimab:** a fully human monoclonal antibody targeting programmed death-ligand 1 (PD-L1)[3][4], functioning as an immune checkpoint inhibitor to enhance antitumor immune responses by blocking PD-L1 interaction with PD-1, thereby restoring T-cell activation. - **Donafenib:** a small molecule tyrosine kinase inhibitor (TKI), specifically a deuterated derivative of sorafenib[2], that inhibits multiple kinases involved in angiogenesis and tumor proliferation. The primary indication for this combination is **advanced or unresectable hepatocellular carcinoma (HCC)**, and it is currently under investigation in clinical trials. The rationale for the combination is to provide synergistic antitumor effects by combining immune checkpoint blockade (sugemalimab) with targeted inhibition of tumor proliferation and angiogenesis (donafenib)[1].